Altheus Therapeutics is categorized under Commercial Medical Research in Oklahoma City, OK and active since 2006.
Altheus Therapeutics was established in 2006, and today employs 1 to 4, earning Unknown per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 5417115 by the NAICS.
If you are seeking more information, feel free to contact Adam Payne at the company’s single location by writing to 755 Research Parkway, Oklahoma City, Oklahoma OK 73104 or by phoning (405) 319-8180. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Altheus Therapeutics |
| Contact Person: | Adam Payne |
| Address: | 755 Research Parkway, Oklahoma City, Oklahoma 73104 |
| Phone Number: | (405) 319-8180 |
| Website Address: | altheustherapeutics.com |
| Annual Revenue (USD): | Unknown |
| Founded: | 2006 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 5417115 |
| Share This Business: |
Altheus Therapeutics was started in 2006 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 5417115. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Adam Payne for inquiries that concern Altheus Therapeutics by calling the company number (405) 319-8180, as your correspondence is most welcome. Additionally, the physical location of the single location of Altheus Therapeutics can be found at the coordinates 35.475996,-97.499995 as well as the street address 755 Research Parkway in Oklahoma City, Oklahoma 73104.
For its online presence, you may visit Altheus Therapeutics’s website at altheustherapeutics.com and engage with its social media outlets through on Twitter and on Facebook.